TMCnet News
Kleo Pharmaceuticals to Present at the LifeSci Partners Summer SymposiumNEW HAVEN, Conn., July 29, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals announced today that Doug Manion, MD, Chief Executive Officer and Chairman of the Board, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. Please click the following link to register: https://lifesci.events/SummerSymposium.
Kleo Pharmaceuticals is a private targeted immunotherapy company with fully synthetic bispecific platform technologies (ARM™ and MATE™) designed to emulate or enhance antibodies. Kleo has a proprietary lead drug candidate, KP1237, entering two separate Phase 1/2 clinical trials in 2020 for multiple myeloma. Further, Kleo is currently engaged in other active collaborations in COVID-19 and oncology indications. For more information, please visit www.kleopharmaceuticals.com. Contacts: Investors Media
|
||||||||
